Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol
Background: Ocular toxoplasmosis (OT) is the most common cause of posterior uveitis, leading to visual impairment in a high proportion of patients. Antibiotics and corticosteroids lower the risk of permanent visual impairment by reducing the size of the retinochoroidal scar, the risk of recurrence,...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2019
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/23361
- Acceso en línea:
- https://doi.org/10.1186/s13643-019-1067-8
https://repository.urosario.edu.co/handle/10336/23361
- Palabra clave:
- Antibiotic agent
Atovaquone
Azithromycin
Ciprofloxacin
Clarithromycin
Clindamycin
Cotrimoxazole
Dapsone
Doxycycline
Erythromycin
Lincomycin
Macrolide
Methotrexate
Minocycline
Miokamycin
Nifurtimox
Pyrimethamine
Rifabutin
Spiramycin
Sulfadoxine
Sulfafurazole
Sulfamerazine
Sulfonamide
Tetracycline
Blurred vision
Chorioretinitis
Eye inflammation
Genetic heterogeneity
Human
Intraocular pressure
Leukocyte count
Meta analysis
Ocular toxoplasmosis
Optic disk
Outcome assessment
Priority journal
Quality control
Randomized controlled trial (topic)
Recurrent disease
Review
Systematic review
Visual acuity
Visual impairment
Anti-bacterial agents
Toxoplasma
Uveitis
ocular
Toxoplasmosis
- Rights
- License
- Abierto (Texto Completo)
id |
EDOCUR2_ff554c1eeba627e24f61456576bd8189 |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/23361 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol |
title |
Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol |
spellingShingle |
Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol Antibiotic agent Atovaquone Azithromycin Ciprofloxacin Clarithromycin Clindamycin Cotrimoxazole Dapsone Doxycycline Erythromycin Lincomycin Macrolide Methotrexate Minocycline Miokamycin Nifurtimox Pyrimethamine Rifabutin Spiramycin Sulfadoxine Sulfafurazole Sulfamerazine Sulfonamide Tetracycline Blurred vision Chorioretinitis Eye inflammation Genetic heterogeneity Human Intraocular pressure Leukocyte count Meta analysis Ocular toxoplasmosis Optic disk Outcome assessment Priority journal Quality control Randomized controlled trial (topic) Recurrent disease Review Systematic review Visual acuity Visual impairment Anti-bacterial agents Toxoplasma Uveitis ocular Toxoplasmosis |
title_short |
Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol |
title_full |
Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol |
title_fullStr |
Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol |
title_full_unstemmed |
Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol |
title_sort |
Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol |
dc.subject.keyword.spa.fl_str_mv |
Antibiotic agent Atovaquone Azithromycin Ciprofloxacin Clarithromycin Clindamycin Cotrimoxazole Dapsone Doxycycline Erythromycin Lincomycin Macrolide Methotrexate Minocycline Miokamycin Nifurtimox Pyrimethamine Rifabutin Spiramycin Sulfadoxine Sulfafurazole Sulfamerazine Sulfonamide Tetracycline Blurred vision Chorioretinitis Eye inflammation Genetic heterogeneity Human Intraocular pressure Leukocyte count Meta analysis Ocular toxoplasmosis Optic disk Outcome assessment Priority journal Quality control Randomized controlled trial (topic) Recurrent disease Review Systematic review Visual acuity Visual impairment Anti-bacterial agents Toxoplasma Uveitis |
topic |
Antibiotic agent Atovaquone Azithromycin Ciprofloxacin Clarithromycin Clindamycin Cotrimoxazole Dapsone Doxycycline Erythromycin Lincomycin Macrolide Methotrexate Minocycline Miokamycin Nifurtimox Pyrimethamine Rifabutin Spiramycin Sulfadoxine Sulfafurazole Sulfamerazine Sulfonamide Tetracycline Blurred vision Chorioretinitis Eye inflammation Genetic heterogeneity Human Intraocular pressure Leukocyte count Meta analysis Ocular toxoplasmosis Optic disk Outcome assessment Priority journal Quality control Randomized controlled trial (topic) Recurrent disease Review Systematic review Visual acuity Visual impairment Anti-bacterial agents Toxoplasma Uveitis ocular Toxoplasmosis |
dc.subject.keyword.eng.fl_str_mv |
ocular Toxoplasmosis |
description |
Background: Ocular toxoplasmosis (OT) is the most common cause of posterior uveitis, leading to visual impairment in a high proportion of patients. Antibiotics and corticosteroids lower the risk of permanent visual impairment by reducing the size of the retinochoroidal scar, the risk of recurrence, and the severity and duration of acute symptoms. Although OT is a very common cause of infectious posterior uveitis, its treatment remains controversial. Through our systematic review and meta-analysis, we aim to provide the best possible evidence-based information on the safety and effectiveness of the different antibiotic regimes for OT. Methods: This systematic review protocol has been developed based on PRISMA-P guidelines for reporting systematic reviews evaluating health care interventions. We will include all published and unpublished randomized controlled trials (RCTs) comparing different antibiotics used for the treatment of OT. We will consider changes in visual acuity, number of recurrences, improvement or worsening of ocular inflammation, size of lesion, and adverse effects as our outcomes. Screening, data extraction, and quality assessment will be undertaken by two reviewers with disagreements resolved through discussion. Studies that compared antibiotics with placebo will be excluded. The reviews will be assessed for quality and relevance. We will assess the risk of bias in five domains according to Cochrane group's tool. The type of data will dictate measures of treatment effect. We will use a random-effects model to calculate our meta-analysis, as eligible studies represent clinically varied populations of participants. Discussion: The strength of our study will lie in the exhaustive and systematic nature of the literature search, as well as in its methods for assessing quality and analyzing RCT data. Considering the controversial efficacy of the treatment for OT, our study will contribute to improving the existing evidence on the effectiveness of different antibiotics. Future studies may be conducted to increase physicians' awareness of antibiotic therapies, improving the health of patients with OT. Systematic review registration: PROSPERO CRD42018085468. © 2019 The Author(s). |
publishDate |
2019 |
dc.date.created.spa.fl_str_mv |
2019 |
dc.date.accessioned.none.fl_str_mv |
2020-05-26T00:01:24Z |
dc.date.available.none.fl_str_mv |
2020-05-26T00:01:24Z |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1186/s13643-019-1067-8 |
dc.identifier.issn.none.fl_str_mv |
20464053 |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/23361 |
url |
https://doi.org/10.1186/s13643-019-1067-8 https://repository.urosario.edu.co/handle/10336/23361 |
identifier_str_mv |
20464053 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationIssue.none.fl_str_mv |
No. 1 |
dc.relation.citationTitle.none.fl_str_mv |
Systematic Reviews |
dc.relation.citationVolume.none.fl_str_mv |
Vol. 8 |
dc.relation.ispartof.spa.fl_str_mv |
Systematic Reviews, ISSN:20464053, Vol.8, No.1 (2019) |
dc.relation.uri.spa.fl_str_mv |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067883921&doi=10.1186%2fs13643-019-1067-8&partnerID=40&md5=2bd89c5ab5587fe47ba397b376f65979 |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.acceso.spa.fl_str_mv |
Abierto (Texto Completo) |
rights_invalid_str_mv |
Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
BioMed Central Ltd. |
institution |
Universidad del Rosario |
dc.source.instname.spa.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
bitstream.url.fl_str_mv |
https://repository.urosario.edu.co/bitstreams/7e02f3d5-8aed-4181-84a3-48a9cc239920/download https://repository.urosario.edu.co/bitstreams/900d75d3-4962-4776-b545-69aa747812cd/download https://repository.urosario.edu.co/bitstreams/9601aba4-196b-4608-9637-3088a03397e1/download |
bitstream.checksum.fl_str_mv |
5bfdd9fe1ae94d4ce52d2056695ab3ee edea5be84ca2d3a196b19e795114d98c a47399ef30356150d8d84c6d2eda2757 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1814167517780770816 |
spelling |
029ab59e-5b59-42e3-b8d4-199bcc26eacfc2ac824b-123b-454c-8797-737a529d00dea373ad2e-cce5-4069-8f4c-7175dab885959e1c8ba4-0a0a-4f6e-bf5f-cc59d16a78fb26f8d9d7-47f2-40d2-bb34-5e40e1ad5504e945c156-e98e-4a6d-a727-d211c305742b3e98e801-ced5-4690-a65d-a3f6bb7e6104de1d6a3b-18f8-494f-84c9-ad0594da5d4dd975d6cb-a9d8-4221-a9a9-3de14928a5ec517013556002020-05-26T00:01:24Z2020-05-26T00:01:24Z2019Background: Ocular toxoplasmosis (OT) is the most common cause of posterior uveitis, leading to visual impairment in a high proportion of patients. Antibiotics and corticosteroids lower the risk of permanent visual impairment by reducing the size of the retinochoroidal scar, the risk of recurrence, and the severity and duration of acute symptoms. Although OT is a very common cause of infectious posterior uveitis, its treatment remains controversial. Through our systematic review and meta-analysis, we aim to provide the best possible evidence-based information on the safety and effectiveness of the different antibiotic regimes for OT. Methods: This systematic review protocol has been developed based on PRISMA-P guidelines for reporting systematic reviews evaluating health care interventions. We will include all published and unpublished randomized controlled trials (RCTs) comparing different antibiotics used for the treatment of OT. We will consider changes in visual acuity, number of recurrences, improvement or worsening of ocular inflammation, size of lesion, and adverse effects as our outcomes. Screening, data extraction, and quality assessment will be undertaken by two reviewers with disagreements resolved through discussion. Studies that compared antibiotics with placebo will be excluded. The reviews will be assessed for quality and relevance. We will assess the risk of bias in five domains according to Cochrane group's tool. The type of data will dictate measures of treatment effect. We will use a random-effects model to calculate our meta-analysis, as eligible studies represent clinically varied populations of participants. Discussion: The strength of our study will lie in the exhaustive and systematic nature of the literature search, as well as in its methods for assessing quality and analyzing RCT data. Considering the controversial efficacy of the treatment for OT, our study will contribute to improving the existing evidence on the effectiveness of different antibiotics. Future studies may be conducted to increase physicians' awareness of antibiotic therapies, improving the health of patients with OT. Systematic review registration: PROSPERO CRD42018085468. © 2019 The Author(s).application/pdfhttps://doi.org/10.1186/s13643-019-1067-820464053https://repository.urosario.edu.co/handle/10336/23361engBioMed Central Ltd.No. 1Systematic ReviewsVol. 8Systematic Reviews, ISSN:20464053, Vol.8, No.1 (2019)https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067883921&doi=10.1186%2fs13643-019-1067-8&partnerID=40&md5=2bd89c5ab5587fe47ba397b376f65979Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURAntibiotic agentAtovaquoneAzithromycinCiprofloxacinClarithromycinClindamycinCotrimoxazoleDapsoneDoxycyclineErythromycinLincomycinMacrolideMethotrexateMinocyclineMiokamycinNifurtimoxPyrimethamineRifabutinSpiramycinSulfadoxineSulfafurazoleSulfamerazineSulfonamideTetracyclineBlurred visionChorioretinitisEye inflammationGenetic heterogeneityHumanIntraocular pressureLeukocyte countMeta analysisOcular toxoplasmosisOptic diskOutcome assessmentPriority journalQuality controlRandomized controlled trial (topic)Recurrent diseaseReviewSystematic reviewVisual acuityVisual impairmentAnti-bacterial agentsToxoplasmaUveitisocularToxoplasmosisAntibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocolarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Feliciano-Alfonso, John E.Vargas-Villanueva, AndrésMarín, María AlejandraTriviño, LauraCarvajal, NataliaMoreno, ManuelaLuna, TatianaLopez de Mesa, ClaraMuñoz-Ortiz, Julianade-la-Torre, AlejandraORIGINALs13643-019-1067-8.pdfapplication/pdf611441https://repository.urosario.edu.co/bitstreams/7e02f3d5-8aed-4181-84a3-48a9cc239920/download5bfdd9fe1ae94d4ce52d2056695ab3eeMD51TEXTs13643-019-1067-8.pdf.txts13643-019-1067-8.pdf.txtExtracted texttext/plain33703https://repository.urosario.edu.co/bitstreams/900d75d3-4962-4776-b545-69aa747812cd/downloadedea5be84ca2d3a196b19e795114d98cMD52THUMBNAILs13643-019-1067-8.pdf.jpgs13643-019-1067-8.pdf.jpgGenerated Thumbnailimage/jpeg4278https://repository.urosario.edu.co/bitstreams/9601aba4-196b-4608-9637-3088a03397e1/downloada47399ef30356150d8d84c6d2eda2757MD5310336/23361oai:repository.urosario.edu.co:10336/233612022-05-02 07:37:15.965658https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |